22 August 2018
Visiongain’s new report Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis indicates that the global Inflammatory Bowel Diseases drug market will see $9.5bn in spending in 2020.
The global inflammatory bowel diseases (IBD) drug market is estimated at $8.5bn in 2016 and $9.5bn in 2020. Biologic therapies are expected to be the main drivers of growth in the world IBD drug market over the forecast period. In 2016, the biologics submarket generated revenues of $5.8bn, accounting for 68% of the global IBD drug market.
The lead analyst of the report said: “The worldwide inflammatory bowel drug market will show moderate sales growth over the next four years from 2016. Patent expiries for Humira and Remicade during our forecast period will bring the market value significantly lower. New drugs entering the market are not expected to be able to offset this loss.
The increased use of biologics will be the main sales driver to 2027. Aminosalicylates, however, will remain an important option for patients, especially those in poor countries, as the cost advantage of aminosalicylates will be more pronounced in those regions.”
The 200-page report contains 89 tables and 50 figures that add visual analysis in order to explain the developing trends within the Global Inflammatory Bowel Diseases drug market. Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments of this market: Biologics, Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators.
Our study forecasts individual revenues of 17 leading IBD drugs, including these drugs: Humira, Remicade, Asacol, Pentasa, Lialda, Tysabri.
This report also discusses research and development, including drug candidates in these classes: Interleukin (IL) inhibitors, Cell-adhesion molecule (CAM) inhibitors, TNF-alpha inhibitors, Stem cell therapies, JAK inhibitors and Toll-like receptor agonists.
The 200-page report offers market forecasts and analysis for 11 leading national markets and the rest of the world market. In addition, the report contains a dedicated leading companies’ chapter covering companies leading the field in the inflammatory bowel diseases drug market.
The Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis report will be of value to anyone who wants to better understand the Global Inflammatory Bowel Diseases drug market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of Global Inflammatory Bowel Diseases drug market and industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The technologies that will be in the greatest demand in this decade are those that provide flexibility and faster turnover times for pharma companies.
19 August 2019
Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.
15 August 2019
The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.
06 August 2019
The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.